Can a patient with a remote history of stroke and cardiac disease be a candidate for Spravato (esketamine)?

Can This Patient Be a Candidate for Spravato?

A patient with a remote history of stroke and cardiac disease is NOT an absolute contraindication to Spravato, but requires careful cardiovascular risk assessment before initiation, with particular attention to current blood pressure control, absence of aneurysmal vascular disease, and ability to tolerate transient BP elevations.

Absolute Contraindications to Rule Out First

The FDA label for Spravato provides clear contraindications that must be excluded 1:

• Aneurysmal vascular disease (brain, chest, abdominal aorta, arms, legs)
• Arteriovenous malformation
• History of intracerebral hemorrhage
• Allergy to esketamine or ketamine

If your patient has any of these conditions, Spravato is contraindicated regardless of how remote the stroke or cardiac history is.

Critical Cardiovascular Assessment Required

Blood Pressure Considerations

Spravato causes predictable BP elevations in all patients 1:

• Peak BP increase occurs at ~40 minutes post-dose
• Duration: approximately 4 hours
• Magnitude: Mean increases of 13-16 mmHg systolic and 8-10 mmHg diastolic 2
• 3-19% of patients experience increases ≥40 mmHg systolic or ≥25 mmHg diastolic 1

Before each dose, BP must be <140/90 mmHg 1. If elevated, delay dosing and reassess the risk-benefit balance for that session.

Specific Cardiac History Concerns

The FDA label states that "patients with other cardiovascular and cerebrovascular conditions should be carefully assessed to determine whether the potential benefits outweigh risks" 1. This is where clinical judgment becomes critical:

For remote stroke history:

• If the stroke was ischemic and occurred long ago with good recovery, this is NOT an absolute contraindication
• Key question: Does the patient have underlying aneurysmal disease or AV malformation? If yes, contraindicated
• Monitor more intensively if history of hypertensive encephalopathy 1

For cardiac disease history:

• Clinical trials excluded patients with uncontrolled hypertension (>140/>90 mmHg) and clinically significant ECG abnormalities 2
• However, stable, controlled cardiovascular disease was not an exclusion in the long-term safety studies 3
• Real-world data shows esketamine can be used safely in patients with various comorbidities when appropriately monitored 4

Monitoring Protocol Required

If you proceed with Spravato, implement this monitoring algorithm 1:

1. Pre-dose: Check BP; must be <140/90 mmHg to proceed
2. 40 minutes post-dose: Measure BP (peak effect time)
3. Continue monitoring for at least 2 hours until BP declines
4. If BP remains elevated or patient develops symptoms (chest pain, shortness of breath, severe headache, visual changes, seizures), seek emergency care immediately

Safety Data Supporting Use in Cardiovascular Patients

The cardiac safety study of esketamine included 1,708 patients and found 2:

• BP elevations were "generally transient, asymptomatic, and not associated with serious cardiovascular safety sequelae"
• Only 3 serious cardiovascular adverse events related to BP increase occurred
• <2% discontinued due to BP or tachycardia issues
• No clinically relevant ECG changes or QTc prolongation

Long-term data (up to 1 year) showed 3:

• Manageable safety profile with sustained antidepressant effects
• No cases of respiratory depression
• Most adverse events were mild-moderate and resolved same day

Common Pitfalls to Avoid

1. Don't assume "remote" history means no risk - You must actively rule out aneurysmal disease and current uncontrolled hypertension
2. Don't skip pre-dose BP checks - This is a safety requirement, not a suggestion
3. Don't discharge patients early - The 2-hour monitoring period is mandatory because BP effects can persist
4. Don't use if patient takes MAOIs or psychostimulants without intensive BP monitoring 1

Bottom Line Decision Algorithm

YES, proceed with Spravato if:

• No aneurysmal vascular disease, AV malformation, or intracerebral hemorrhage history
• Current BP controlled (<140/90 mmHg)
• Able to monitor BP for 2+ hours post-dose
• Patient understands and accepts transient cardiovascular effects

NO, do not use Spravato if:

• Any absolute contraindication present (aneurysm, AV malformation, ICH history)
• Uncontrolled hypertension despite treatment
• Unable to provide adequate post-dose monitoring
• Recent (<12 months) acute coronary syndrome or unstable cardiac disease requiring more conservative approach

The "long time ago" nature of the stroke and cardiac history actually works in your patient's favor, as acute/unstable disease poses greater concern than remote, stable conditions.